Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ American Well Corporation (AMWL) Stock Forecast & Price Prediction United States | NYSE | Healthcare | Health Information Services
$11.01
+1.10 (11.10%)Did AMWL Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if American Well is one of their latest high-conviction picks.
Based on our analysis of 3 Wall Street analysts, AMWL has a neutral consensus with a median price target of $7.50 (ranging from $6.50 to $9.00). The overall analyst rating is Buy (6.6/10). Currently trading at $11.01, the median forecast implies a -31.9% downside. This outlook is supported by 1 Buy, 6 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Craig Hettenbach at Morgan Stanley, suggesting a 41.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for AMWL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 6, 2026 | TD Cowen | Charles Rhyee | Hold | Maintains | $8.00 |
| May 6, 2026 | Morgan Stanley | Craig Hettenbach | Equal-Weight | Maintains | $6.50 |
| Feb 13, 2026 | Stifel | Hold | Maintains | $N/A | |
| Dec 18, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Nov 5, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Nov 5, 2025 | Stifel | Hold | Maintains | $N/A | |
| Aug 7, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| May 23, 2025 | Piper Sandler | Neutral | Reiterates | $N/A | |
| May 8, 2025 | UBS | Neutral | Maintains | $N/A | |
| May 2, 2025 | Stifel | Hold | Maintains | $N/A | |
| May 2, 2025 | Needham | Hold | Reiterates | $N/A | |
| Apr 10, 2025 | Truist Securities | Hold | Maintains | $N/A | |
| Feb 14, 2025 | Truist Securities | Hold | Maintains | $N/A | |
| Feb 13, 2025 | Stifel | Hold | Maintains | $N/A | |
| Feb 13, 2025 | Needham | Hold | Reiterates | $N/A | |
| Jan 13, 2025 | Wells Fargo | Overweight | Upgrade | $N/A | |
| Dec 17, 2024 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Oct 31, 2024 | Needham | Hold | Reiterates | $N/A | |
| Sep 24, 2024 | Needham | Hold | Reiterates | $N/A | |
| Aug 6, 2024 | Wells Fargo | Equal-Weight | Maintains | $N/A |
The following stocks are similar to American Well based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
American Well Corporation has a market capitalization of $183.96M with a P/E ratio of -1.9x. The company generates $237.38M in trailing twelve-month revenue with a -37.0% profit margin.
Revenue growth is -17.9% quarter-over-quarter, while maintaining an operating margin of -23.6% and return on equity of -31.8%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Provides telemedicine technology for healthcare access.
American Well Corporation operates by connecting patients with healthcare professionals through its telemedicine platform, generating revenue from healthcare providers, insurers, and employers who subscribe to its services. The company earns money by enabling video consultations and other virtual healthcare solutions, thus facilitating a more efficient healthcare delivery system.
The company plays a significant role in the digital health transformation, addressing the increasing demand for flexible and accessible healthcare services. Its technology is utilized in various settings, including hospitals and health plans, highlighting its versatility and importance in both public and private healthcare sectors.
Healthcare
Health Information Services
562
Dr. Ido Schoenberg M.D.
United States
2020
American Well (AMWL) shares rose significantly with higher-than-average trading volume; however, recent earnings estimate revisions may not lead to additional price increases soon.
The surge in American Well's shares with high trading volume indicates strong market interest, but mixed earnings estimates suggest potential volatility ahead for the stock price.
American Well (AMWL) has been upgraded to a Zacks Rank #2 (Buy) due to increasing optimism about its earnings prospects, indicating potential for stock price growth.
The upgrade to Zacks Rank #2 signals increased confidence in American Well's earnings potential, likely attracting investor interest and driving stock price appreciation.
American Well (AMWL) has shown strong recent momentum and is considered a good investment option, as it passes the 'Fast-Paced Momentum at a Bargain' screening criteria.
American Well (AMWL) shows strong momentum while remaining reasonably priced, highlighting potential for growth and value, attracting investors seeking opportunities in the market.
American Well Corporation (AMWL) and Butterfly Network, Inc. (BFLY) are being compared to their sector's performance for the year. Further details on specific performance metrics were not provided.
Performance comparisons highlight the relative strength or weakness of American Well Corporation and Butterfly Network against their sector, influencing investment decisions and market sentiment.
American Well (AMWL) has shown strong recent momentum and is considered a good investment option, passing the 'Fast-Paced Momentum at a Bargain' screening criteria.
American Well (AMWL) shows strong momentum while remaining reasonably priced, indicating potential for growth and profitability, appealing to value-seeking investors.
Amwell (NYSE: AMWL) announced results from a National Institute of Mental Health-funded trial published in Nature Human Behaviour, focusing on its digital behavioral health solution, SilverCloudยฎ.
Positive trial results for Amwell's SilverCloudยฎ could enhance its market position in digital health, potentially driving stock value and attracting investor interest in the growing telehealth sector.
Based on our analysis of 3 Wall Street analysts, American Well Corporation (AMWL) has a median price target of $7.50. The highest price target is $9.00 and the lowest is $6.50.
According to current analyst ratings, AMWL has 1 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.01. Always conduct your own research and consider your investment goals before making investment decisions.
Wall Street analysts predict AMWL stock could reach $7.50 in the next 12 months. This represents a -31.9% decrease from the current price of $11.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
American Well Corporation operates by connecting patients with healthcare professionals through its telemedicine platform, generating revenue from healthcare providers, insurers, and employers who subscribe to its services. The company earns money by enabling video consultations and other virtual healthcare solutions, thus facilitating a more efficient healthcare delivery system.
The highest price target for AMWL is $9.00 from at , which represents a -18.3% decrease from the current price of $11.01.
The lowest price target for AMWL is $6.50 from Craig Hettenbach at Morgan Stanley, which represents a -41.0% decrease from the current price of $11.01.
The overall analyst consensus for AMWL is neutral. Out of 3 Wall Street analysts, 1 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $7.50.
Stock price projections, including those for American Well Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.